✦ LIBER ✦

Fluvoxamine as an Adjunctive Agent in Schizophrenia

✍ Scribed by Henry Silver

Book ID: 109105571
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 174 KB
Volume: 7
Category: Article
ISSN: 1080-563X
DOI: 10.1111/j.1527-3458.2001.tb00200.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Time as an adjunctive agent to thromboly

Time as an adjunctive agent to thrombolytic therapy

✍ Christopher P. Cannon; Elliott M. Antman; Ron Walls; Eugene Braunwald 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 860 KB

P.3.036 - Pramipexole as an adjunct to h

P.3.036 - Pramipexole as an adjunct to haloperidol in schizophrenia

✍ C. Barnas; A. Heiden; H.P. Volz; G. Laakmannc; H. Zeit; H. Pfolz; S. Kasper 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Eicosapentaenoic acid (EPA) as an adjunc

Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia

✍ S. Shah; G.K. Vankar; S.D. Telang; C.N. Ramchand; M. Peet 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 95 KB

Allopurinol may have potential as an adj

Allopurinol may have potential as an adjunctive therapy in patients with schizophrenia,

📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Fluvoxamine augmentation in chronic schi

Fluvoxamine augmentation in chronic schizophrenia: An open exploratory study

✍ Henry Silver; Alla Kaplan; Mina Kushnir 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB

The effect of augmenting standard antipsychotic treatment with the specific serotonergic reuptake inhibitor (SSRI) fluvoxamine was examined in severely disabled chronic schizophrenic inpatients using an open, naturalistic protocol. Fluvoxamine in doses ranging from 25 to 200 mg was added to the ant

Fluvoxamine augmentation in risperidone-

Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial

✍ Hitoshi Takashi; Takio Sugita; Hisashi Higuchi; Tetsuo Shimizu 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB 👁 1 views

We investigated the efficacy and safety of augmenting risperidone with fluvoxamine for the treatment of residual positive and negative symptoms in patients with chronic schizophrenia who had shown an incomplete response to risperidone. A total of 30 patients completed the open trial over a 12-week p